Home › Funds › BVF INC/IL › GLUE
BVF INC/IL position in GLUE
MONTE ROSA THERAPEUTICS INC · Health Care
BVF INC/IL reported holding 4,460,886 shares of GLUE (MONTE ROSA THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$108.0M, representing 2.76% of its reported portfolio and ranking #11 among its reported holdings. BVF INC/IL has disclosed GLUE holdings in 7 of the last 7 reported quarters, going back to Q4 2024.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How BVF INC/IL's GLUE position evolved
BVF INC/IL first disclosed a stake in GLUE in Q4 2024 at 2,764,471 shares (US$19.2M). The position peaked in Q2 2026 at 4,460,886 shares, worth US$108.0M. Across 7 filings, BVF INC/IL increased the stake 2 time(s), trimmed it 1 time(s) and left it unchanged 3 time(s). The most recent filing (Q2 2026) shows 4,460,886 shares valued at US$108.0M. Notable position changes include a 105% increase in Q1 2025 (shares fell 3% over the following quarter), a 32% trim in Q4 2025 (shares rose 5% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2024 | 2.76M | $19.19M | New |
| Q1 2025 | 5.66M | $26.26M | Add |
| Q2 2025 | 5.66M | $25.53M | Hold |
| Q3 2025 | 5.66M | $41.94M | Hold |
| Q4 2025 | 3.84M | $60.15M | Reduce |
| Q1 2026 | 4.46M | $73.38M | Add |
| Q2 2026 | 4.46M | $107.95M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About GLUE and 13F data
GLUE (MONTE ROSA THERAPEUTICS INC) is a Health Care company. 73 other funds we track also report a position in GLUE — the largest reported positions include NEA Management Company, LLC (US$186.2M), TCG Crossover Management, LLC (US$111.9M), Vestal Point Capital, LP (US$111.3M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding GLUE
- NEA Management Company, LLC 7.69M sh · $186.15M · Q2 2026
- TCG Crossover Management, LLC 4.62M sh · $111.86M · Q2 2026
- Vestal Point Capital, LP 4.60M sh · $111.32M · Q2 2026
- BAKER BROS. ADVISORS LP 4.35M sh · $105.17M · Q2 2026
- MONTANOVA CAPITAL, LLC 3.55M sh · $85.90M · Q2 2026
- Versant Venture Management, LLC 3.18M sh · $76.97M · Q2 2026
- BRAIDWELL LP 2.45M sh · $59.33M · Q2 2026
- Aisling Capital Management LP 1.56M sh · $37.65M · Q2 2026
- Bellevue Group AG 1.19M sh · $28.80M · Q2 2026
- MPM BioImpact LLC 1.16M sh · $28.10M · Q2 2026
- Frazier Life Sciences Management, L.P. 1.00M sh · $24.20M · Q2 2026
- Nextech Invest Ltd. 761.15K sh · $18.42M · Q2 2026
FAQ
How long has BVF INC/IL held GLUE?
BVF INC/IL has disclosed GLUE holdings in 7 of the last 7 reported quarters, going back to Q4 2024.
What is BVF INC/IL's current position in GLUE?
As of Q2 2026, BVF INC/IL holds 4.46M shares of GLUE (MONTE ROSA THERAPEUTICS INC), valued at $107.95M, representing 2.76% of its reported portfolio and ranking #11.
Has BVF INC/IL been buying or selling GLUE?
In the latest 13F filing (Q2 2026), BVF INC/IL held unchanged its position in GLUE. The position peaked in Q2 2026 at 4.46M shares.
Which other funds hold GLUE?
Other major institutional holders of GLUE include NEA Management Company, LLC, TCG Crossover Management, LLC, Vestal Point Capital, LP, among 73 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.